Yangzijiang pharmaceutical group regards quality benefiting people as its main development strategy to realize sound development

China Medical Science and technology award 2013, the highest award in the national pharmaceutical and health industry, was held in Beijing on January 8, 2013 In February, it became the only enterprise in the pharmaceutical industry in Jiangsu province that won the "Jiangsu Quality Award" The longfengtang high tech Industrial Park project of traditional Chinese Medicine with a total investment of 2 billion yuan has recently been fully launched along the river in Gaogang, Taizhou Since the start of this year, the good news related to Yangzijiang Pharmaceutical Group has been constantly uploaded from the market, which has greatly improved the brand awareness and reputation of the company, which has been ranked the top 3 in the national pharmaceutical industry for four consecutive years "The state vigorously advocates the development of large-scale health industry, bringing new development opportunities to pharmaceutical enterprises In the face of the new situation, Yangzijiang pharmaceutical group should adhere to the road of strengthening enterprises by science and technology and by quality, and take quality for the benefit of the people as the main development strategy " Xu Jingren, chairman of the group, believes that "the vitality of the company is due to the needs of users and the eternal pursuit of product quality." At present, Yangzijiang Pharmaceutical Group has produced more than 20 dosage forms and more than 200 product specifications, most of which are injections with the highest quality requirements However, it has kept 100% of the qualified rate of the quality spot check conducted by the pharmaceutical supervision department for many years, and has become one of the enterprises with the best drug quality recognized by the society In 2013, the group's Weidi products won the "people's reassurance drug Award" in the 9th survey and selection of safe drug use among the people held by the drug administration department of the national health and Family Planning Commission and the health newspaper Yangzijiang pharmaceutical group regards brand quality as the lifeline of the enterprise, strictly controls drug R & D, purchase, production, release, storage and after-sale, and establishes a set of enterprise internal control standards higher than the legal standards At the same time, in March and September of each year, the whole staff double quality month activity has been carried out for 15 consecutive years The introduction, training, training and bold use of quality science and technology talents is an important starting point for Yangzijiang Pharmaceutical Group to improve its quality management system In order to let Weng Xintai, who once served as the Deputy technical director and senior manager of the quality department of Shanghai Roche Pharmaceutical Co., Ltd and had rich experience in quality management, "go out of the mountain", Xu Jingren moved him to be the group's chief quality engineer with the sincerity of "three Gu moulu" Under the leadership of Weng Xintai, the No 2 solid preparation workshop of Yangzijiang Pharmaceutical Group successfully obtained the EU GMP (good production quality management standard) Certificate in 2010 At present, the group has introduced 8 excellent doctors from Tsinghua University, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, China Pharmaceutical University and other institutions of higher learning, and 5 of them have completed the practical training in the workshop and taken the leadership position They lead the group's quality and technical personnel to carry out research and improvement of a number of quality systems, so that the group's quality management has reached a higher level and level It is another pioneering work of Yangzijiang Pharmaceutical Group to invite national and provincial drug inspection "judges" into the plant and track the whole process of drug production, storage and quality inspection As early as six years ago, CFDA has set up its training base in the group, and has sent 10 batches of 80 person time testing technicians to come for training In 2012, Jiangsu food and Drug Administration and provincial drug inspection institute also successively built training bases here In recent years, these "judges" have directly guided enterprises to solve more than 100 problems Not only that, they also go deep into the workshop and laboratory to carry out face-to-face training, so that group employees can learn new methods and skills of quality inspection In order to further promote the quality management of the whole staff, Yangzijiang Pharmaceutical Group has also set up more than 100 QC groups in the production, scientific research and quality front line of the enterprise to carry out quality improvement, technological innovation and technological research activities all year round Up to now, the group has carried out more than 600 research activities, and more than 10 QC achievements have filled in the technical gaps at home and abroad, creating hundreds of millions of yuan of economic benefits for enterprises Among the many office buildings in the headquarters of Yangtze River Pharmaceutical Group, the R & D building is the most magnificent, and the working environment and equipment of R & D personnel are also the best and most advanced With the joining of a large number of high-level talents such as Dr LV Qiang, expert of the national "thousand talents plan" and chief scientific officer of the group, the group has formed an innovative drug research and development team and department management cadres mainly composed of nearly 100 doctors and more than 300 masters At present, the group devotes more than 3% of its annual sales revenue to technological innovation, with new products accounting for more than 40% of its sales revenue With excellent quality management and strong R & D investment, the group has more than 20 products with quality meeting the standards of European and American Pharmacopoeia By the end of last year, 37 workshops of Yangzijiang pharmaceutical group had fully passed the new GMP certification for preparations and APIs, among which non sterile drugs such as solid preparations and oral liquids were two years ahead of the time limit stipulated by the state, and three workshops had passed the EU GMP certification Xu Jingren said that the adoption of the new GMP is only one of the access conditions for the pharmaceutical industry At present, they are keeping pace with the US FDA standards and accelerating the pace of entering the international mainstream market.